The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis (RA) in patients who have not responded to prior therapy.   
read more http://www.pharmafile.com/news/514154/sanofi-and-regeneron-score-fda-approval-arthritis